|
|
Office Locations:
|
1 Merck Dr.
Whitehouse Station, NJ 08889
Phone: 908-423-1000
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Merck Global Health Innovation Fund (GHI) is a corporate venture fund operated by pharmaceutical concern, Merck. GHI Fund typically invests in Therapy Planning, Care Management, eClinical Trials, Health Analytics & AI with a focus on therapeutic areas aligned with Merck's strengths in Oncology, Immunology & Virology as well as Real Word Evidence. Typical venture investments have current revenue, are close to profitability, and are seeking growth capital. Investments must be attractive on their own, but ideally are an integral part of an ecosystem. The firm's smallest investment is $1.5M and the largest investment is $35M. GHI Fund invests globally, with a focus on North America & Europe. GHI's Evergreen Fund is at $600M with over 60 digital investments.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
